Suzhou Abogen Biosciences Co., Ltd.
๐จ๐ณChina
- Country
- ๐จ๐ณChina
- Ownership
- Holding
- Established
- 2019-01-10
- Employees
- 501
- Market Cap
- -
- Website
- http://www.abogenbio.com
Clinical Trials
4
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)โข Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Phase โ /โ ก Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 218
- Registration Number
- NCT06088004
- Locations
- ๐จ๐ณ
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
๐จ๐ณSun Yat-sen University Cancer Center, Guangzhou, China
๐จ๐ณGuangxi Medical University Cancer Hospital, Nanning, China
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
Phase 2
Active, not recruiting
- Conditions
- COVID-19
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 14168
- Registration Number
- NCT05636319
- Locations
- ๐ฎ๐ฉ
RS Universitas Indonesia, Depok, Indonesia
๐ฎ๐ฉRS YARSI, Jakarta, Indonesia
๐ฎ๐ฉRSIJ Cempaka Putih, Jakarta, Indonesia
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05434585
- Locations
- ๐ฎ๐ฉ
Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
๐ฎ๐ฉPersahabatan Hospital, Jakarta, Indonesia
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19 Omicron) mRNA Vaccine (Phase 1)
Phase 1
- Conditions
- COVID-19
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05433194
- Locations
- ๐ฆ๐ช
AL Kuwait Hospital, Dubai, United Arab Emirates
News
No news found